Lindahl has advised the Norwegian fund Serendipity Partners on the acquisition of 25% of the shares in Bluefish Pharmaceuticals AB.
Bluefish Pharmaceuticals is a Swedish pharmaceutical company active in the development, manufacture and sale of generic drugs. Bluefish’s primary market for sales is the EU, but the company is expanding in areas outside Europe. Its product portfolio consists of approximately 70 products and continues to be developed.
Serendipity manages a fund that invests in companies focused on healthcare. Serendipity is an Oslo-based company that collaborates with founders and owners throughout the healthcare sector, with a particular focus on pharmaceuticals, diagnostics, healthcare providers and medical technology. Serendipity focuses on the Nordic region and Europe and has established a network of experienced leaders with experience from the healthcare sector that complements Bluefish Pharmaceutical’s geographical reach.
Lindahl’s team consisted of Mikael Smedeby, Erika Svensson, Disa Almqvist, Emira Peterson, Olov Kling and Amanda Sjöberg.
For further information about the transaction, see the parties’ press release.
